Azithromycin: Mechanisms of action and their relevance for clinical applications

Pharmacology and Therapeutics

Volumn 143, Issue 2, 2014, Pages 225-245

  Parnham, Michael J ^a,b   Haber, Vesna Erakovic ^c   Giamarellos Bourboulis, Evangelos J ^d,e   Perletti, Gianpaolo ^f,g   Verleden, Geert M ^h   Vos, Robin ^h  

^a FRAUNHOFER INSTITUTE FOR MOLECULAR BIOLOGY AND APPLIED ECOLOGY IME   (Germany)

^b GOETHE UNIVERSITY   (Germany)

^c Xylon Doo   (Croatia)

^d UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

^e JENA UNIVERSITY HOSPITAL   (Germany)

^f UNIVERSITY OF INSUBRIA   (Italy)

^g GHENT UNIVERSITY   (Belgium)

^h UNIVERSITY HOSPITALS LEUVEN   (Belgium)

Author keywords

Azithromycin; Clinical efficacy; Immunomodulation; Macrolide antibiotic; Mechanisms of action; Pharmacokinetics

Indexed keywords

8 ISOPROSTANE; AZITHROMYCIN; CLARITHROMYCIN; COLLAGENASE 3; CXCL3 CHEMOKINE; ERYTHROMYCIN; GELATINASE A; GELATINASE B; GRANULOCYTE CHEMOTACTIC PROTEIN 2; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 18; INTERLEUKIN 6; INTERLEUKIN 8; INTERSTITIAL COLLAGENASE; MITOGEN ACTIVATED PROTEIN KINASE 1; PHOSPHOLIPID; RECEPTOR ACTIVATOR OF NUCLEAR FACTOR KAPPA B; ROXITHROMYCIN; STROMELYSIN 2; ANTIINFECTIVE AGENT; CYTOKINE; MACROLIDE; SIGNAL PEPTIDE; TRANSCRIPTION FACTOR;

ANTIBIOTIC RESISTANCE; APOPTOSIS; AREA UNDER THE CURVE; ARTICLE; ASTHMA; AUTOPHAGY; BLEPHARITIS; BRONCHIECTASIS; BRONCHIOLITIS; BRONCHIOLITIS OBLITERANS ORGANIZING PNEUMONIA; CHRONIC OBSTRUCTIVE LUNG DISEASE; CHRONIC PROSTATITIS; CONJUNCTIVITIS; CYSTIC FIBROSIS; DIFFUSE PANBRONCHIOLITIS; DISEASE EXACERBATION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG HALF LIFE; DRUG MECHANISM; DRUG METABOLISM; DRUG RELEASE; DRUG SAFETY; GENE EXPRESSION; GLOMERULONEPHRITIS; HAEMOPHILUS INFLUENZAE; HUMAN; LEUKOCYTE; LIPID TRANSPORT; LOWER RESPIRATORY TRACT INFECTION; MACROPHAGE; MAXIMUM PLASMA CONCENTRATION; META ANALYSIS; NON CYSTIC FIBROSIS BRONCHIECTASIS; NONHUMAN; PERIODONTAL DISEASE; PERIODONTITIS; PHARMACEUTICAL CARE; PLASMA CONCENTRATION-TIME CURVE; PRIORITY JOURNAL; PROSTATITIS; PROTEIN EXPRESSION; SEPSIS; SKIN DISEASE; STOMACH MOTILITY; STREPTOCOCCUS PNEUMONIAE; STREPTOCOCCUS PYOGENES; SYSTEMATIC REVIEW; TIME TO MAXIMUM PLASMA CONCENTRATION; UPPER RESPIRATORY TRACT INFECTION; URETHRITIS; BACTERIAL INFECTIONS; EPITHELIUM CELL; GENETICS; IMMUNOMODULATION; LYSOSOME; METABOLISM; PATHOPHYSIOLOGY; PHAGOCYTE; PHYSIOLOGY;

ANTI-BACTERIAL AGENTS; AZITHROMYCIN; BACTERIAL INFECTIONS; CYTOKINES; DRUG RESISTANCE, BACTERIAL; EPITHELIAL CELLS; HUMANS; IMMUNOMODULATION; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; LYSOSOMES; MACROLIDES; PHAGOCYTES; PHOSPHOLIPIDS; TRANSCRIPTION FACTORS;

EID: 84902550867     PISSN: 01637258     EISSN: 1879016X     Source Type: Journal    
DOI: 10.1016/j.pharmthera.2014.03.003     Document Type: Review

References (315)

1. N. Adriaenssens, S. Coenen, A.C. Kroes, A. Versporten, V. Vankerckhoven, and A. Muller et al. European Surveillance of Antimicrobial Consumption (ESAC): systemic antiviral use in Europe J Antimicrob Chemother 66 2011 1897 1905
2. Z.H. Aghai, A. Kode, J.G. Saslow, T. Nakhla, S. Farhath, and G.E. Stahl et al. Azithromycin suppresses activation of nuclear factor-kappa B and synthesis of pro-inflammatory cytokines in tracheal aspirate cells from premature infants Pediatr Res 62 2007 483 488
3. R.K. Albert, J. Connett, W.C. Bailey, R. Casaburi, J.A. Cooper Jr., and G.J. Criner et al. Azithromycin for prevention of exacerbations of COPD N Engl J Med 365 2011 689 698
4. N.E. Allen Effects of macrolide antibiotics on ribosome function W. Schönfeld, H.A. Kirst, Macrolide antibiotics 2002 Birkhäuser Verlag Basel 261 280
5. J. Altenburg, C.S. de Graaff, Y. Stienstra, J.H. Sloos, E.H. van Haren, and R.J. Koppers et al. Effect of azithromycin maintenance treatment on infectious exacerbations among patients with non-cystic fibrosis bronchiectasis: the BAT randomized controlled trial JAMA 309 2013 1251 1259
6. A.A. Alzolibani, and K. Zedan Macrolides in chronic inflammatory skin disorders Mediators Inflamm 2012 2012 159354
7. L. Amado-Rodriguez, A. Gonzalez-Lopez, I. Lopez-Alonso, A. Aguirre, A. Astudillo, and E. Batalla-Solis et al. Anti-inflammatory effects of clarithromycin in ventilator-induced lung injury Respir Res 14 2013 52
8. L. Ambroggio, J.A. Taylor, L.P. Tabb, C.J. Newschaffer, A.A. Evans, and S.S. Shah Comparative effectiveness of empiric beta-lactam monotherapy and beta-lactam-macrolide combination therapy in children hospitalized with community-acquired pneumonia J Pediatr 161 2012 1097 1103
9. G.W. Amsden Macrolides versus azalides: a drug interaction update Ann Pharmacother 29 1995 906 917
10. G.W. Amsden Erythromycin, clarithromycin, and azithromycin: are the differences real? Clin Ther 18 1996 56 72 (discussion 55)
11. G.W. Amsden Advanced-generation macrolides: tissue-directed antibiotics Int J Antimicrob Agents 18 Suppl. 1 2001 S11 S15
12. G.W. Amsden Anti-inflammatory effects of macrolides - an underappreciated benefit in the treatment of community-acquired respiratory tract infections and chronic inflammatory pulmonary conditions? J Antimicrob Chemother 55 2005 10 21
13. G.A. Anwar, S.C. Bourke, G. Afolabi, P. Middleton, C. Ward, and R.M. Rutherford Effects of long-term low-dose azithromycin in patients with non-CF bronchiectasis Respir Med 102 2008 1494 1496
14. N. Araki, K. Yanagihara, Y. Morinaga, K. Yamada, S. Nakamura, and Y. Yamada et al. Azithromycin inhibits nontypeable Haemophilus influenzae-induced MUC5AC expression and secretion via inhibition of activator protein-1 in human airway epithelial cells Eur J Pharmacol 644 2010 209 214
15. L. Asadi, D.T. Eurich, J.M. Gamble, J.K. Minhas-Sandhu, T.J. Marrie, and S.R. Majumdar Impact of guideline-concordant antibiotics and macrolide/beta-lactam combinations in 3203 patients hospitalized with pneumonia: prospective cohort study Clin Microbiol Infect 19 2013 257 264
16. L. Asadi, W.I. Sligl, D.T. Eurich, I.N. Colmers, L. Tjosvold, and T.J. Marrie et al. Macrolide-based regimens and mortality in hospitalized patients with community-acquired pneumonia: a systematic review and meta-analysis Clin Infect Dis 55 2012 371 380
17. E. Asakura, H. Nakayama, M. Sugie, Y.L. Zhao, M. Nadai, and K. Kitaichi et al. Azithromycin reverses anticancer drug resistance and modifies hepatobiliary excretion of doxorubicin in rats Eur J Pharmacol 484 2004 333 339
18. V. Asgrimsson, T. Gudjonsson, G.H. Gudmundsson, and O. Baldursson Novel effects of azithromycin on tight junction proteins in human airway epithelia Antimicrob Agents Chemother 50 2006 1805 1812
19. S. Atmatzidis, I. Koutelidakis, G. Chatzimavroudis, K. Louis, A. Pistiki, and K. Roditis et al. Clarithromycin modulates immune responses in experimental peritonitis Int J Antimicrob Agents 37 2011 347 351
20. M. Baciu, S.C. Sebai, O. Ces, X. Mulet, J.A. Clarke, and G.C. Shearman et al. Degradative transport of cationic amphiphilic drugs across phospholipid bilayers Philos Transact A Math Phys Eng Sci 364 2006 2597 2614
21. O. Bakar, Z. Demircay, M. Yuksel, G. Haklar, and Y. Sanisoglu The effect of azithromycin on reactive oxygen species in rosacea Clin Exp Dermatol 32 2007 197 200
22. H.O. Ballard, P. Bernard, J. Qualls, W. Everson, and L.A. Shook Azithromycin protects against hyperoxic lung injury in neonatal rats J Investig Med 55 2007 299 305
23. C.H. Ballow, G.W. Amsden, V.S. Highet, and A. Forrest Pharmacokinetics of oral azithromycin in serum, urine, polymorphonuclear leucocytes and inflammatory vs non-inflammatory skin blisters in healthy volunteers Clin Drug Investig 15 1998 159 167
24. M. Banjanac, V. Munic Kos, K. Nujic, M. Vrancic, D. Belamaric, and S. Crnkovic et al. Anti-inflammatory mechanism of action of azithromycin in LPS-stimulated J774A.1 cells Pharmacol Res 66 2012 357 362
25. P.M. Bartold, A.H. du Bois, S. Gannon, D.R. Haynes, and R.S. Hirsch Antibacterial and immunomodulatory properties of azithromycin treatment implications for periodontitis Inflammopharmacology 21 2013 321 338
26. A. Beigelman, S. Gunsten, C.L. Mikols, I. Vidavsky, C.L. Cannon, and S.L. Brody et al. Azithromycin attenuates airway inflammation in a noninfectious mouse model of allergic asthma Chest 136 2009 498 506
27. A. Beigelman, C.L. Mikols, S.P. Gunsten, C.L. Cannon, S.L. Brody, and M.J. Walter Azithromycin attenuates airway inflammation in a mouse model of viral bronchiolitis Respir Res 11 2010 90
28. J.F. Bermejo-Martin, D.J. Kelvin, J.M. Eiros, J. Castrodeza, and R. Ortiz de Lejarazu Macrolides for the treatment of severe respiratory illness caused by novel H1N1 swine influenza viral strains J Infect Dev Ctries 3 2009 159 161
29. A.M. Binder, J. Adjemian, K.N. Olivier, and D.R. Prevots Epidemiology of nontuberculous mycobacterial infections and associated chronic macrolide use among persons with cystic fibrosis Am J Respir Crit Care Med 188 2013 807 812
30. F. Blasi, D. Bonardi, S. Aliberti, P. Tarsia, M. Confalonieri, and O. Amir et al. Long-term azithromycin use in patients with chronic obstructive pulmonary disease and tracheostomy Pulm Pharmacol Ther 23 2010 200 207
31. J.M. Blondeau, E. DeCarolis, K.L. Metzler, and G.T. Hansen The macrolides Expert Opin Investig Drugs 11 2002 189 215
32. I. Bookman, J.W. Scholey, S.V. Jassal, G. Lajoie, and A.M. Herzenberg Necrotizing glomerulonephritis caused by Bartonella henselae endocarditis Am J Kidney Dis 43 2004 e25 e30
33. J.S. Boomer, K. To, K.C. Chang, O. Takasu, D.F. Osborne, and A.H. Walton et al. Immunosuppression in patients who die of sepsis and multiple organ failure JAMA 306 2011 2594 2605
34. M. Bosnar, B. Bosnjak, S. Cuzic, B. Hrvacic, N. Marjanovic, and I. Glojnaric et al. Azithromycin and clarithromycin inhibit lipopolysaccharide- induced murine pulmonary neutrophilia mainly through effects on macrophage-derived granulocyte-macrophage colony-stimulating factor and interleukin-1beta J Pharmacol Exp Ther 331 2009 104 113
35. M. Bosnar, S. Cuzic, B. Bosnjak, K. Nujic, G. Ergovic, and N. Marjanovic et al. Azithromycin inhibits macrophage interleukin-1beta production through inhibition of activator protein-1 in lipopolysaccharide-induced murine pulmonary neutrophilia Int Immunopharmacol 11 2011 424 434
36. M. Bosnar, Z. Kelneric, V. Munic, V. Erakovic, and M.J. Parnham Cellular uptake and efflux of azithromycin, erythromycin, clarithromycin, telithromycin, and cethromycin Antimicrob Agents Chemother 49 2005 2372 2377
37. M. Bosnar, G. Kragol, S. Kostrun, I. Vujasinovic, B. Bosnjak, and V. Bencetic Mihaljevic et al. N′-substituted-2′-O,3′-N- carbonimidoyl bridged macrolides: novel anti-inflammatory macrolides without antimicrobial activity J Med Chem 55 2012 6111 6123
38. E. Branden, H. Koyi, J. Gnarpe, H. Gnarpe, and G. Tornling Intermittent azithromycin treatment for respiratory symptoms in patients with chronic Chlamydia pneumoniae infection Scand J Infect Dis 36 2004 811 816
39. Bright, G.M. & Hauske, J.R. (1984). Azahomoerythromycin D derivative and intermediates thereof. US Patent 4,465,674 A.
40. J. Broad, and G.J. Sanger The antibiotic azithromycin is a motilin receptor agonist in human stomach: comparison with erythromycin Br J Pharmacol 168 2013 1859 1867
41. I. Brook Sinusitis of odontogenic origin Otolaryngol Head Neck Surg 135 2006 349 355
42. G.G. Brusselle, C. Vanderstichele, P. Jordens, R. Deman, H. Slabbynck, and V. Ringoet et al. Azithromycin for prevention of exacerbations in severe asthma (AZISAST): a multicentre randomised double-blind placebo-controlled trial Thorax 68 2013 322 329
43. B. Butorac-Petanjek, M.J. Parnham, and S. Popovic-Grle Antibiotic therapy for exacerbations of chronic obstructive pulmonary disease (COPD) J Chemother 22 2010 291 297
44. E.J. Cameron, C. McSharry, R. Chaudhuri, S. Farrow, and N.C. Thomson Long-term macrolide treatment of chronic inflammatory airway diseases: risks, benefits and future developments Clin Exp Allergy 42 2012 1302 1312
45. O. Carevic, and S. Djokic Comparative studies on the effects of erythromycin A and azithromycin upon extracellular release of lysosomal enzymes in inflammatory processes Agents Actions 25 1988 124 131
46. M.B. Carlier, I. Garcia-Luque, J.P. Montenez, P.M. Tulkens, and J. Piret Accumulation, release and subcellular localization of azithromycin in phagocytic and non-phagocytic cells in culture Int J Tissue React 16 1994 211 220
47. W.S. Champney, and R. Burdine Azithromycin and clarithromycin inhibition of 50S ribosomal subunit formation in Staphylococcus aureus cells Curr Microbiol 36 1998 119 123
48. W.S. Champney, C.L. Tober, and R. Burdine A comparison of the inhibition of translation and 50S ribosomal subunit formation in Staphylococcus aureus cells by nine different macrolide antibiotics Curr Microbiol 37 1998 412 417
49. C. Cigana, E. Nicolis, M. Pasetto, B.M. Assael, and P. Melotti Anti-inflammatory effects of azithromycin in cystic fibrosis airway epithelial cells Biochem Biophys Res Commun 350 2006 977 982
50. A. Clement, A. Tamalet, E. Leroux, S. Ravilly, B. Fauroux, and J.P. Jais Long term effects of azithromycin in patients with cystic fibrosis: a double blind, placebo controlled trial Thorax 61 2006 895 902
51. P. Coates, R. Daniel, A.C. Houston, J.H. Antrobus, and T. Taylor An open study to compare the pharmacokinetics, safety and tolerability of a multiple-dose regimen of azithromycin in young and elderly volunteers Eur J Clin Microbiol Infect Dis 10 1991 850 852
52. P.M. Coloma, M.J. Schuemie, G. Trifiro, L. Furlong, E. van Mulligen, and A. Bauer-Mehren et al. Drug-induced acute myocardial infarction: identifying 'prime suspects' from electronic healthcare records-based surveillance system PLoS One 8 2013 e72148
53. O. Culic, V. Erakovic, I. Cepelak, K. Barisic, K. Brajsa, and Z. Ferencic et al. Azithromycin modulates neutrophil function and circulating inflammatory mediators in healthy human subjects Eur J Pharmacol 450 2002 277 289
54. O. Culic, V. Erakovic, and M.J. Parnham Anti-inflammatory effects of macrolide antibiotics Eur J Pharmacol 429 2001 209 229
55. W. Curatolo, P. Liu, B.A. Johnson, A. Hausberger, E. Quan, and T. Vendola et al. Effects of food on a gastrically degraded drug: azithromycin fast-dissolving gelatin capsules and HPMC capsules Pharm Res 28 2011 1531 1539
56. C. Daenas, A.A. Hatziefthimiou, K.I. Gourgoulianis, and P.A. Molyvdas Azithromycin has a direct relaxant effect on precontracted airway smooth muscle Eur J Pharmacol 553 2006 280 287
57. E.L. Dahl, and P.J. Rosenthal Multiple antibiotics exert delayed effects against the Plasmodium falciparum apicoplast Antimicrob Agents Chemother 51 2007 3485 3490
58. R.P. Dellinger, M.M. Levy, A. Rhodes, D. Annane, H. Gerlach, and S.M. Opal et al. Surviving sepsis campaign: international guidelines for management of severe sepsis and septic shock: 2012 Crit Care Med 41 2013 580 637
59. C.D. den Heijer, E.M. van Bijnen, W.J. Paget, M. Pringle, H. Goossens, and C.A. Bruggeman et al. Prevalence and resistance of commensal Staphylococcus aureus, including meticillin-resistant S. aureus, in nine European countries: a cross-sectional study Lancet Infect Dis 13 2013 409 415
60. A. Di Paolo, C. Barbara, A. Chella, C.A. Angeletti, and M. Del Tacca Pharmacokinetics of azithromycin in lung tissue, bronchial washing, and plasma in patients given multiple oral doses of 500 and 1000 mg daily Pharmacol Res 46 2002 545 550
61. R. Dias, and M. Canica Emergence of invasive erythromycin-resistant Streptococcus pneumoniae strains in Portugal: contribution and phylogenetic relatedness of serotype 14 J Antimicrob Chemother 54 2004 1035 1039
62. G.P. Dinos, M. Michelinaki, and D.L. Kalpaxis Insights into the mechanism of azithromycin interaction with an Escherichia coli functional ribosomal complex Mol Pharmacol 59 2001 1441 1445
63. A. Ehnhage, M. Rautiainen, A.F. Fang, and S.P. Sanchez Pharmacokinetics of azithromycin in serum and sinus fluid after administration of extended-release and immediate-release formulations in patients with acute bacterial sinusitis Int J Antimicrob Agents 31 2008 561 566
64. V. Erakovic Haber, M. Bosnar, and G. Kragol Design of novel classes of macrolides for neutrophil dominated inflammatory diseases Future Medicinal Chemistry 6 2014 in press
65. E.J. Ernst, M.E. Klepser, T.B. Klepser, C.H. Nightingale, and L.G. Hunsicker Comparison of the serum and intracellular pharmacokinetics of azithromycin in healthy and diabetic volunteers Pharmacotherapy 20 2000 657 661
66. S. Esposito, S. Bosis, N. Faelli, E. Begliatti, R. Droghetti, and E. Tremolati et al. Role of atypical bacteria and azithromycin therapy for children with recurrent respiratory tract infections Pediatr Infect Dis J 24 2005 438 444
67. N. Fa, L. Lins, P.J. Courtoy, Y. Dufrene, P. Van Der Smissen, and R. Brasseur et al. Decrease of elastic moduli of DOPC bilayers induced by a macrolide antibiotic, azithromycin Biochim Biophys Acta 1768 2007 1830 1838
68. L. Falk, H. Fredlund, and J.S. Jensen Tetracycline treatment does not eradicate Mycoplasma genitalium Sex Transm Infect 79 2003 318 319
69. A.F. Fang, J.N. Palmer, A.G. Chiu, J.L. Blumer, P.H. Crownover, and M.D. Campbell et al. Pharmacokinetics of azithromycin in plasma and sinus mucosal tissue following administration of extended-release or immediate-release formulations in adult patients with chronic rhinosinusitis Int J Antimicrob Agents 34 2009 67 71
70. D.J. Farrell, and S.G. Jenkins Distribution across the USA of macrolide resistance and macrolide resistance mechanisms among Streptococcus pneumoniae isolates collected from patients with respiratory tract infections: PROTEKT US 2001-2002 J Antimicrob Chemother 54 Suppl. 1 2004 i17 i22
71. M. Federica, S. Nadia, M. Monica, C. Alessandro, O. Tiberio, and B. Francesco et al. Clinical and immunological evaluation of 12-month azithromycin therapy in chronic lung allograft rejection Clin Transplant 25 2011 E381 E389
72. D. Felmingham, and R.N. Gruneberg The Alexander Project 1996-1997: latest susceptibility data from this international study of bacterial pathogens from community-acquired lower respiratory tract infections J Antimicrob Chemother 45 2000 191 203
73. D.J. Feola, B.A. Garvy, T.J. Cory, S.E. Birket, H. Hoy, and D. Hayes Jr. et al. Azithromycin alters macrophage phenotype and pulmonary compartmentalization during lung infection with Pseudomonas Antimicrob Agents Chemother 54 2010 2437 2447
74. A.C. Fernandes, R. Anderson, A.J. Theron, G. Joone, and C.E. Van Rensburg Enhancement of human polymorphonuclear leucocyte motility by erythromycin in vitro and in vivo S Afr Med J 66 1984 173 177
75. P. Fernandez-Robredo, S. Recalde, M. Moreno-Orduna, L. Garcia-Garcia, J. Zarranz-Ventura, and A. Garcia-Layana Azithromycin reduces inflammation in a rat model of acute conjunctivitis Mol Vis 19 2013 153 165
76. A.D. Fernandez, M.K. Elmore, and D.W. Metzger Azithromycin modulates murine immune responses to pneumococcal conjugate vaccine and inhibits nasal clearance of bacteria J Infect Dis 190 2004 1762 1766
77. G.M. Fimia, and M. Piacentini Regulation of autophagy in mammals and its interplay with apoptosis Cell Mol Life Sci 67 2010 1581 1588
78. J.L. Fleet, S.Z. Shariff, D.G. Bailey, S. Gandhi, D.N. Juurlink, and D.M. Nash et al. Comparing two types of macrolide antibiotics for the purpose of assessing population-based drug interactions BMJ Open 3 2013
79. O. Florey, and M. Overholtzer Autophagy proteins in macroendocytic engulfment Trends Cell Biol 22 2012 374 380
80. G. Foulds, P. Madsen, C. Cox, R. Shepard, and R. Johnson Concentration of azithromycin in human prostatic tissue Eur J Clin Microbiol Infect Dis 10 1991 868 871
81. G. Foulds, R.M. Shepard, and R.B. Johnson The pharmacokinetics of azithromycin in human serum and tissues J Antimicrob Chemother 25 Suppl. A 1990 73 82
82. F. Franceschi, Z. Kanyo, E.C. Sherer, and J. Sutcliffe Macrolide resistance from the ribosome perspective Curr Drug Targets Infect Disord 4 2004 177 191
83. E. Garver, E.D. Hugger, S.P. Shearn, A. Rao, P.A. Dawson, and C.B. Davis et al. Involvement of intestinal uptake transporters in the absorption of azithromycin and clarithromycin in the rat Drug Metab Dispos 36 2008 2492 2498
84. T. Gebre, B. Ayele, M. Zerihun, A. Genet, N.E. Stoller, and Z. Zhou et al. Comparison of annual versus twice-yearly mass azithromycin treatment for hyperendemic trachoma in Ethiopia: a cluster-randomised trial Lancet 379 2012 143 151
85. C. Gerbaux, F. Van Bambeke, J.P. Montenez, J. Piret, G. Morlighem, and P.M. Tulkens Hyperactivity of cathepsin B and other lysosomal enzymes in fibroblasts exposed to azithromycin, a dicationic macrolide antibiotic with exceptional tissue accumulation FEBS Lett 394 1996 307 310
86. S.G. Gerhardt, J.F. McDyer, R.E. Girgis, J.V. Conte, S.C. Yang, and J.B. Orens Maintenance azithromycin therapy for bronchiolitis obliterans syndrome: results of a pilot study Am J Respir Crit Care Med 168 2003 121 125
87. N. Geudens, L. Timmermans, H. Vanhooren, B.M. Vanaudenaerde, R. Vos, and C. Van De Wauwer et al. Azithromycin reduces airway inflammation in a murine model of lung ischaemia reperfusion injury Transpl Int 21 2008 688 695
88. E.J. Giamarellos-Bourboulis, V. Mylona, A. Antonopoulou, I. Tsangaris, I. Koutelidakis, and A. Marioli et al. Effect of clarithromycin in patients with suspected Gram-negative sepsis: results of a randomized controlled trial J Antimicrob Chemother 2013 10.1093/jac/dkt475
89. E.J. Giamarellos-Bourboulis, J.C. Pechere, C. Routsi, D. Plachouras, S. Kollias, and M. Raftogiannis et al. Effect of clarithromycin in patients with sepsis and ventilator-associated pneumonia Clin Infect Dis 46 2008 1157 1164
90. A. Giannopoulos, G. Koratzanis, E.J. Giamarellos-Bourboulis, C. Panou, I. Adamakis, and H. Giamarellou Pharmacokinetics of clarithromycin in the prostate: implications for the treatment of chronic abacterial prostatitis J Urol 165 2001 97 99
91. V. Gielen, S.L. Johnston, and M.R. Edwards Azithromycin induces anti-viral responses in bronchial epithelial cells Eur Respir J 36 2010 646 654
92. E. Giovanetti, A. Brenciani, R. Burioni, and P.E. Varaldo A novel efflux system in inducibly erythromycin-resistant strains of Streptococcus pyogenes Antimicrob Agents Chemother 46 2002 3750 3755
93. E. Giovanetti, M.P. Montanari, M. Mingoia, and P.E. Varaldo Phenotypes and genotypes of erythromycin-resistant Streptococcus pyogenes strains in Italy and heterogeneity of inducibly resistant strains Antimicrob Agents Chemother 43 1999 1935 1940
94. J.R. Giudicessi, and M.J. Ackerman Azithromycin and risk of sudden cardiac death: guilty as charged or falsely accused? Cleve Clin J Med 80 2013 539 544
95. R.P. Gladue, G.M. Bright, R.E. Isaacson, and M.F. Newborg In vitro and in vivo uptake of azithromycin (CP-62,993) by phagocytic cells: possible mechanism of delivery and release at sites of infection Antimicrob Agents Chemother 33 1989 277 282
96. R.P. Gladue, and M.E. Snider Intracellular accumulation of azithromycin by cultured human fibroblasts Antimicrob Agents Chemother 34 1990 1056 1060
97. I. Glojnaric, S. Cuzic, V. Erakovic-Haber, and M.J. Parnham The serum amyloid A response to sterile silver nitrate in mice and its inhibition by dexamethasone and macrolide antibiotics Int Immunopharmacol 7 2007 1544 1551
98. K. Gomi, A. Yashima, F. Iino, M. Kanazashi, T. Nagano, and N. Shibukawa et al. Drug concentration in inflamed periodontal tissues after systemically administered azithromycin J Periodontol 78 2007 918 923
99. J. Gottlieb, J. Szangolies, T. Koehnlein, H. Golpon, A. Simon, and T. Welte Long-term azithromycin for bronchiolitis obliterans syndrome after lung transplantation Transplantation 85 2008 36 41
100. S. Halldorsson, T. Gudjonsson, M. Gottfredsson, P.K. Singh, G.H. Gudmundsson, and O. Baldursson Azithromycin maintains airway epithelial integrity during Pseudomonas aeruginosa infection Am J Respir Cell Mol Biol 42 2010 62 68
101. W.L. Hand, and D.L. Hand Characteristics and mechanisms of azithromycin accumulation and efflux in human polymorphonuclear leukocytes Int J Antimicrob Agents 18 2001 419 425
102. J.L. Hansen, J.A. Ippolito, N. Ban, P. Nissen, P.B. Moore, and T.A. Steitz The structures of four macrolide antibiotics bound to the large ribosomal subunit Mol Cell 10 2002 117 128
103. K. Hao, Q. Qi, H. Hao, G. Wang, Y. Chen, and Y. Liang et al. The pharmacokinetic-pharmacodynamic model of azithromycin for lipopolysaccharide- induced depressive-like behavior in mice PLoS One 8 2013 e54981
104. H.E. Hassan, A.A. Othman, N.D. Eddington, L. Duffy, L. Xiao, and K.B. Waites et al. Pharmacokinetics, safety, and biologic effects of azithromycin in extremely preterm infants at risk for ureaplasma colonization and bronchopulmonary dysplasia J Clin Pharmacol 51 2011 1264 1275
105. D.P. Healy, P.A. Silverman, A.N. Neely, I.A. Holder, and G.E. Babcock Effect of antibiotics on polymorphonuclear neutrophil apoptosis Pharmacotherapy 22 2002 578 585
106. D.C. Henry, E. Riffer, W.N. Sokol, N.I. Chaudry, and R.N. Swanson Randomized double-blind study comparing 3- and 6-day regimens of azithromycin with a 10-day amoxicillin-clavulanate regimen for treatment of acute bacterial sinusitis Antimicrob Agents Chemother 47 2003 2770 2774
107. R. Hirsch, H. Deng, and M.N. Laohachai Azithromycin in periodontal treatment: more than an antibiotic J Periodontal Res 47 2012 137 148
108. S. Hodge, G. Hodge, S. Brozyna, H. Jersmann, M. Holmes, and P.N. Reynolds Azithromycin increases phagocytosis of apoptotic bronchial epithelial cells by alveolar macrophages Eur Respir J 28 2006 486 495
109. S. Hodge, G. Hodge, H. Jersmann, G. Matthews, J. Ahern, and M. Holmes et al. Azithromycin improves macrophage phagocytic function and expression of mannose receptor in chronic obstructive pulmonary disease Am J Respir Crit Care Med 178 2008 139 148
110. S. Hodge, and P.N. Reynolds Low-dose azithromycin improves phagocytosis of bacteria by both alveolar and monocyte-derived macrophages in chronic obstructive pulmonary disease subjects Respirology 17 2012 802 807
111. D. Hoffler, P. Koeppe, and B. Paeske Pharmacokinetics of azithromycin in normal and impaired renal function Infection 23 1995 356 361
112. N. Hoffmann, B. Lee, M. Hentzer, T.B. Rasmussen, Z. Song, and H.K. Johansen et al. Azithromycin blocks quorum sensing and alginate polymer formation and increases the sensitivity to serum and stationary-growth-phase killing of Pseudomonas aeruginosa and attenuates chronic P. aeruginosa lung infection in Cftr(-/-) mice Antimicrob Agents Chemother 51 2007 3677 3687
113. N. Hoiby Recent advances in the treatment of Pseudomonas aeruginosa infections in cystic fibrosis BMC Med 9 2011 32
114. A. Ianaro, A. Ialenti, P. Maffia, L. Sautebin, L. Rombola, and R. Carnuccio et al. Anti-inflammatory activity of macrolide antibiotics J Pharmacol Exp Ther 292 2000 156 163
115. K. Ikeda, M. Hirayama, Y. Hirota, E. Asa, J. Seki, and Y. Tanaka Drug-induced phospholipidosis is caused by blockade of mannose 6-phosphate receptor-mediated targeting of lysosomal enzymes Biochem Biophys Res Commun 377 2008 268 274
116. S. Ikegaya, K. Inai, H. Iwasaki, H. Naiki, and T. Ueda Azithromycin reduces tumor necrosis factor-alpha production in lipopolysaccharide-stimulated THP-1 monocytic cells by modification of stress response and p38 MAPK pathway J Chemother 21 2009 396 402
117. Y. Imamura, K. Yanagihara, Y. Mizuta, M. Seki, H. Ohno, and Y. Higashiyama et al. Azithromycin inhibits MUC5AC production induced by the Pseudomonas aeruginosa autoinducer N-(3-Oxododecanoyl) homoserine lactone in NCI-H292 Cells Antimicrob Agents Chemother 48 2004 3457 3461
118. M. Inoue, D.J. Farrell, K. Kaneko, K. Akizawa, S. Fujita, and M. Kaku et al. Antimicrobial susceptibility of respiratory tract pathogens in Japan during PROTEKT years 1-5 (1999-2004) Microb Drug Resist 14 2008 109 117
119. Y. Ishimatsu, J. Kadota, T. Iwashita, T. Nagata, H. Ishii, and C. Shikuwa et al. Macrolide antibiotics induce apoptosis of human peripheral lymphocytes in vitro Int J Antimicrob Agents 24 2004 247 253
120. H. Ishimoto, H. Mukae, N. Sakamoto, M. Amenomori, T. Kitazaki, and Y. Imamura et al. Different effects of telithromycin on MUC5AC production induced by human neutrophil peptide-1 or lipopolysaccharide in NCI-H292 cells compared with azithromycin and clarithromycin J Antimicrob Chemother 63 2009 109 114
121. V. Ivetic Tkalcevic, B. Bosnjak, B. Hrvacic, M. Bosnar, N. Marjanovic, and Z. Ferencic et al. Anti-inflammatory activity of azithromycin attenuates the effects of lipopolysaccharide administration in mice Eur J Pharmacol 539 2006 131 138
122. V. Ivetic Tkalcevic, S. Cuzic, M.D. Kramaric, M.J. Parnham, and V. Erakovic Haber Topical azithromycin and clarithromycin inhibit acute and chronic skin inflammation in sensitized mice, with apparent selectivity for Th2-mediated processes in delayed-type hypersensitivity Inflammation 35 2012 192 205
123. S. Iwamoto, E. Azuma, T. Kumamoto, M. Hirayama, T. Yoshida, and M. Ito et al. Efficacy of azithromycin in preventing lethal graft-versus-host disease Clin Exp Immunol 171 2013 338 345
124. S. Iwamoto, T. Kumamoto, E. Azuma, M. Hirayama, M. Ito, and K. Amano et al. The effect of azithromycin on the maturation and function of murine bone marrow-derived dendritic cells Clin Exp Immunol 166 2011 385 392
125. M.R. Jacobs, and C.E. Johnson Macrolide resistance: an increasing concern for treatment failure in children Pediatr Infect Dis J 22 2003 S131 S138
126. R.F. Jacobs, H.D. Maples, J.V. Aranda, G.M. Espinoza, C. Knirsch, and R. Chandra et al. Pharmacokinetics of intravenously administered azithromycin in pediatric patients Pediatr Infect Dis J 24 2005 34 39
127. S.G. Jenkins, S.D. Brown, and D.J. Farrell Trends in antibacterial resistance among Streptococcus pneumoniae isolated in the USA: update from PROTEKT US Years 1-4 Ann Clin Microbiol Antimicrob 7 2008 1
128. J.S. Ju, and C.C. Weihl Inclusion body myopathy, Paget's disease of the bone and fronto-temporal dementia: a disorder of autophagy Hum Mol Genet 19 2010 R38 R45
129. S. Kannan, and T.K. Mattoo Diffuse crescentic glomerulonephritis in bacterial endocarditis Pediatr Nephrol 16 2001 423 428
130. S. Kanoh, and B.K. Rubin Mechanisms of action and clinical application of macrolides as immunomodulatory medications Clin Microbiol Rev 23 2010 590 615
131. J. Karhu, T.I. Ala-Kokko, P. Ohtonen, and H. Syrjala Severe community-acquired pneumonia treated with beta-lactam-respiratory quinolone vs. beta-lactam-macrolide combination Acta Anaesthesiol Scand 57 2013 587 593
132. O.I. Karpov The clinical and economic efficacies of short courses of azithromycin in acute sinusitis Antibiot Khimioter 44 1999 28 32
133. J.R. Kent, M.K. Almond, and S. Dhillon Azithromycin: an assessment of its pharmacokinetics and therapeutic potential in CAPD Perit Dial Int 21 2001 372 377
134. A. Kezerashvili, H. Khattak, A. Barsky, R. Nazari, and J.D. Fisher Azithromycin as a cause of QT-interval prolongation and torsade de pointes in the absence of other known precipitating factors J Interv Card Electrophysiol 18 2007 243 246
135. O.A. Khair, J.L. Devalia, M.M. Abdelaziz, R.J. Sapsford, and R.J. Davies Effect of erythromycin on Haemophilus influenzae endotoxin-induced release of IL-6, IL-8 and sICAM-1 by cultured human bronchial epithelial cells Eur Respir J 8 1995 1451 1457
136. A.A. Khan, T.R. Slifer, F.G. Araujo, and J.S. Remington Effect of clarithromycin and azithromycin on production of cytokines by human monocytes Int J Antimicrob Agents 11 1999 121 132
137. E. Kita, M. Sawaki, F. Nishikawa, K. Mikasa, Y. Yagyu, and S. Takeuchi et al. Enhanced interleukin production after long-term administration of erythromycin stearate Pharmacology 41 1990 177 183
138. M.C. Kneyber, J.B. van Woensel, E. Uijtendaal, C.S. Uiterwaal, J.L. Kimpen Dutch Antibiotics in, R. S. V. T. R. G Azithromycin does not improve disease course in hospitalized infants with respiratory syncytial virus (RSV) lower respiratory tract disease: a randomized equivalence trial Pediatr Pulmonol 43 2008 142 149
139. H. Kobayashi, N. Ohgaki, and H. Takeda Therapeutic possibilities for diffuse panbronchiolitis Int J Antimicrob Agents 3 Suppl. 1 1993 S81 S86
140. Y. Kobayashi, H. Wada, C. Rossios, D. Takagi, M. Higaki, and S. Mikura et al. A novel macrolide solithromycin exerts superior anti-inflammatory effect via NF-kappaB inhibition J Pharmacol Exp Ther 345 2013 76 84
141. Kobrehel, G., Radobolja, G., Tamburasev, Z., Djokic, S. (1982). 11-Aza-10-deoxo-10-dihydroerythromycin A and derivatives thereof as well as a process for their preparation. U.S. Patent 4,328,334.
142. C.C. Koch, D.J. Esteban, A.C. Chin, M.E. Olson, R.R. Read, and H. Ceri et al. Apoptosis, oxidative metabolism and interleukin-8 production in human neutrophils exposed to azithromycin: effects of Streptococcus pneumoniae J Antimicrob Chemother 46 2000 19 26
143. T. Kohler, J.L. Dumas, and C. Van Delden Ribosome protection prevents azithromycin-mediated quorum-sensing modulation and stationary-phase killing of Pseudomonas aeruginosa Antimicrob Agents Chemother 51 2007 4243 4248
144. A. Kolumbic Lakos, V. Skerk, G. Malekovic, T. Dujnic Spoljarevic, D. Kovacic, and M. Pasini et al. A switch therapy protocol with intravenous azithromycin and ciprofloxacin combination for severe, relapsing chronic bacterial prostatitis: a prospective non-comparative pilot study J Chemother 23 2011 350 353
145. S. Konno, M. Adachi, K. Asano, T. Kawazoe, K. Okamoto, and T. Takahashi Influences of roxithromycin on cell-mediated immune responses Life Sci 51 1992 L107 L112
146. S. Kornfeld Structure and function of the mannose 6-phosphate/insulinlike growth factor II receptors Annu Rev Biochem 61 1992 307 330
147. S. Kosol, E. Schrank, M.B. Krajacic, G.E. Wagner, N.H. Meyer, and C. Gobl et al. Probing the interactions of macrolide antibiotics with membrane-mimetics by NMR spectroscopy J Med Chem 55 2012 5632 5636
148. A. Kotsaki, and E.J. Giamarellos-Bourboulis Emerging drugs for the treatment of sepsis Expert Opin Emerg Drugs 17 2012 379 391
149. S. Kudoh Applying lessons learned in the treatment of diffuse panbronchiolitis to other chronic inflammatory diseases Am J Med 117 Suppl. 9A 2004 12S 19S
150. S. Kudoh, A. Azuma, M. Yamamoto, T. Izumi, and M. Ando Improvement of survival in patients with diffuse panbronchiolitis treated with low-dose erythromycin Am J Respir Crit Care Med 157 1998 1829 1832
151. A.K. Lakos, A. Pangercic, M. Gasparic, M.M. Kukuruzovic, D. Kovacic, and B. Barsic Safety and effectiveness of azithromycin in the treatment of respiratory infections in children Curr Med Res Opin 28 2012 155 162
152. C.Y. Lau, and A.K. Qureshi Azithromycin versus doxycycline for genital chlamydial infections: a meta-analysis of randomized clinical trials Sex Transm Dis 29 2002 497 502
153. R. Leclercq Mechanisms of resistance to macrolides and lincosamides: nature of the resistance elements and their clinical implications Clin Infect Dis 34 2002 482 492
154. R. Legssyer, F. Huaux, J. Lebacq, M. Delos, E. Marbaix, and P. Lebecque et al. Azithromycin reduces spontaneous and induced inflammation in DeltaF508 cystic fibrosis mice Respir Res 7 2006 134
155. H. Li, D.H. Liu, L.L. Chen, Q. Zhao, Y.Z. Yu, and J.J. Ding et al. Adverse effects of long-term azithromycin use in patients with chronic lung diseases: a meta-analysis Antimicrob Agents Chemother 58 2013 511 517
156. H. Li, Y. Zhou, F. Fan, Y. Zhang, X. Li, and H. Yu et al. Effect of azithromycin on patients with diffuse panbronchiolitis: retrospective study of 51 cases Intern Med 50 2011 1663 1669
157. H.C. Lin, C.H. Wang, C.Y. Liu, C.T. Yu, and H.P. Kuo Erythromycin inhibits beta2-integrins (CD11b/CD18) expression, interleukin-8 release and intracellular oxidative metabolism in neutrophils Respir Med 94 2000 654 660
158. S.J. Lin, D.C. Yan, W.I. Lee, M.L. Kuo, H.S. Hsiao, and P.Y. Lee Effect of azithromycin on natural killer cell function Int Immunopharmacol 13 2012 8 14
159. P. Liu, A.F. Fang, R.R. LaBadie, P.H. Crownover, and A.G. Arguedas Comparison of azithromycin pharmacokinetics following single oral doses of extended-release and immediate-release formulations in children with acute otitis media Antimicrob Agents Chemother 55 2011 5022 5026
160. H. Lode, K. Borner, P. Koeppe, and T. Schaberg Azithromycin - review of key chemical, pharmacokinetic and microbiological features J Antimicrob Chemother 37 Suppl. C 1996 1 8
161. M. Lucchi, B. Damle, A. Fang, P.J. de Caprariis, A. Mussi, and S.P. Sanchez et al. Pharmacokinetics of azithromycin in serum, bronchial washings, alveolar macrophages and lung tissue following a single oral dose of extended or immediate release formulations of azithromycin J Antimicrob Chemother 61 2008 884 891
162. J. Luchs Azithromycin in DuraSite for the treatment of blepharitis Clin Ophthalmol 4 2010 681 688
163. D.R. Luke, and G. Foulds Disposition of oral azithromycin in humans Clin Pharmacol Ther 61 1997 641 648
164. L. Luo, J.M. Perelman, V.P. Kolosov, and X.D. Zhou Inhibition of airway mucous hypersecretion by azithromycin through matrix metalloproteinase 9 Zhonghua Yi Xue Za Zhi 91 2011 689 693
165. L. Lutz, D.C. Pereira, R.M. Paiva, A.P. Zavascki, and A.L. Barth Macrolides decrease the minimal inhibitory concentration of anti-pseudomonal agents against Pseudomonas aeruginosa from cystic fibrosis patients in biofilm BMC Microbiol 12 2012 196
166. V. Magri, E. Marras, V. Skerk, A. Markotic, A. Restelli, and M.C. Garlaschi et al. Eradication of Chlamydia trachomatis parallels symptom regression in chronic bacterial prostatitis patients treated with a fluoroquinolone-macrolide combination Andrologia 42 2010 366 375
167. V. Magri, A. Trinchieri, G. Pozzi, A. Restelli, M.C. Garlaschi, and E. Torresani et al. Efficacy of repeated cycles of combination therapy for the eradication of infecting organisms in chronic bacterial prostatitis Int J Antimicrob Agents 29 2007 549 556
168. S. Malhotra-Kumar, C. Lammens, S. Coenen, K. Van Herck, and H. Goossens Effect of azithromycin and clarithromycin therapy on pharyngeal carriage of macrolide-resistant streptococci in healthy volunteers: a randomised, double-blind, placebo-controlled study Lancet 369 2007 482 490
169. J.M. Mann, K.K. Sha, G. Kline, F.U. Breuer, and A. Miller World Trade Center dyspnea: bronchiolitis obliterans with functional improvement: a case report Am J Ind Med 48 2005 225 229
170. N. Marjanovic, M. Bosnar, F. Michielin, D.R. Wille, T. Anic-Milic, and O. Culic et al. Macrolide antibiotics broadly and distinctively inhibit cytokine and chemokine production by COPD sputum cells in vitro Pharmacol Res 63 2011 389 397
171. B.F. Marple, C.S. Roberts, J.R. Frytak, V.F. Schabert, J.C. Wegner, and H. Bhattacharyya et al. Azithromycin extended release vs amoxicillin/ clavulanate: symptom resolution in acute sinusitis Am J Otolaryngol 31 2010 1 8
172. I. Martin-Loeches, T. Lisboa, A. Rodriguez, C. Putensen, D. Annane, and J. Garnacho-Montero et al. Combination antibiotic therapy with macrolides improves survival in intubated patients with community-acquired pneumonia Intensive Care Med 36 2010 612 620
173. F. Massei, L. Gori, P. Macchia, and G. Maggiore The expanded spectrum of bartonellosis in children Infect Dis Clin North Am 19 2005 691 711
174. M. Matijasic, V. Munic Kos, K. Nujic, S. Cuzic, J. Padovan, and G. Kragol et al. Fluorescently labeled macrolides as a tool for monitoring cellular and tissue distribution of azithromycin Pharmacol Res 66 2012 332 342
175. Y. Matsumura, A. Mitani, T. Suga, Y. Kamiya, T. Kikuchi, and S. Tanaka et al. Azithromycin may inhibit interleukin-8 through suppression of Rac1 and a nuclear factor-kappa B pathway in KB cells stimulated with lipopolysaccharide J Periodontol 82 2011 1623 1631
176. P. Matzneller, S. Krasniqi, M. Kinzig, F. Sorgel, S. Huttner, and E. Lackner et al. Blood, tissue, and intracellular concentrations of azithromycin during and after end of therapy Antimicrob Agents Chemother 57 2013 1736 1742
177. T. Mazzei, C. Surrenti, A. Novelli, A. Crispo, S. Fallani, and V. Carla et al. Pharmacokinetics of azithromycin in patients with impaired hepatic function J Antimicrob Chemother 31 Suppl. E 1993 57 63
178. P.J. McDonald, and H. Pruul Phagocyte uptake and transport of azithromycin Eur J Clin Microbiol Infect Dis 10 1991 828 833
179. L.A. Mena, T.F. Mroczkowski, M. Nsuami, and D.H. Martin A randomized comparison of azithromycin and doxycycline for the treatment of Mycoplasma genitalium-positive urethritis in men Clin Infect Dis 48 2009 1649 1654
180. A. Mencarelli, E. Distrutti, B. Renga, S. Cipriani, G. Palladino, and C. Booth et al. Development of non-antibiotic macrolide that corrects inflammation-driven immune dysfunction in models of inflammatory bowel diseases and arthritis Eur J Pharmacol 665 2011 29 39
181. K.A. Mergenhagen, P.M. Olbrych, A. Mattappallil, M.P. Krajewski, and M.C. Ott Effect of azithromycin on anticoagulation-related outcomes in geriatric patients receiving warfarin Clin Ther 35 2013 425 430
182. V. Mertens, K. Blondeau, A. Pauwels, R. Farre, B. Vanaudenaerde, and R. Vos et al. Azithromycin reduces gastroesophageal reflux and aspiration in lung transplant recipients Dig Dis Sci 54 2009 972 979
183. M.L. Metersky, A. Ma, P.M. Houck, and D.W. Bratzler Antibiotics for bacteremic pneumonia: improved outcomes with macrolides but not fluoroquinolones Chest 131 2007 466 473
184. M. Meyer, F. Huaux, X. Gavilanes, S. van den Brule, P. Lebecque, and S. Lo Re et al. Azithromycin reduces exaggerated cytokine production by M1 alveolar macrophages in cystic fibrosis Am J Respir Cell Mol Biol 41 2009 590 602
185. P. Milberg, L. Eckardt, H.J. Bruns, J. Biertz, S. Ramtin, and N. Reinsch et al. Divergent proarrhythmic potential of macrolide antibiotics despite similar QT prolongation: fast phase 3 repolarization prevents early afterdepolarizations and torsade de pointes J Pharmacol Exp Ther 303 2002 218 225
186. S.A. Miller, C.H. Selzman, B.D. Shames, H.A. Barton, S.M. Johnson, and A.H. Harken Chlamydia pneumoniae activates nuclear factor kappaB and activator protein 1 in human vascular smooth muscle and induces cellular proliferation J Surg Res 90 2000 76 81
187. M. Millrose, M. Kruse, B. Flick, and R. Stahlmann Effects of macrolides on proinflammatory epitopes on endothelial cells in vitro Arch Toxicol 83 2009 469 476
188. J.Y. Min, and Y.J. Jang Macrolide therapy in respiratory viral infections Mediators Inflamm 2012 2012 649570
189. C. Miossec-Bartoli, L. Pilatre, P. Peyron, E.N. N'Diaye, V. Collart-Dutilleul, and I. Maridonneau-Parini et al. The new ketolide HMR3647 accumulates in the azurophil granules of human polymorphonuclear cells Antimicrob Agents Chemother 43 1999 2457 2462
190. M. Miyazaki, M. Zaitsu, K. Honjo, E. Ishii, and Y. Hamasaki Macrolide antibiotics inhibit prostaglandin E2 synthesis and mRNA expression of prostaglandin synthetic enzymes in human leukocytes Prostaglandins Leukot Essent Fatty Acids 69 2003 229 235
191. S. Mizunoe, J. Kadota, I. Tokimatsu, K. Kishi, H. Nagai, and M. Nasu Clarithromycin and azithromycin induce apoptosis of activated lymphocytes via down-regulation of Bcl-xL Int Immunopharmacol 4 2004 1201 1207
192. J.P. Montenez, F. Van Bambeke, J. Piret, R. Brasseur, P.M. Tulkens, and M.P. Mingeot-Leclercq Interactions of macrolide antibiotics (Erythromycin A, roxithromycin, erythromycylamine [Dirithromycin], and azithromycin) with phospholipids: computer-aided conformational analysis and studies on acellular and cell culture models Toxicol Appl Pharmacol 156 1999 129 140
193. J.P. Montenez, F. Van Bambeke, J. Piret, A. Schanck, R. Brasseur, and P.M. Tulkens et al. Interaction of the macrolide azithromycin with phospholipids. II. Biophysical and computer-aided conformational studies Eur J Pharmacol 314 1996 215 227
194. Y. Morinaga, K. Yanagihara, N. Miyashita, M. Seki, K. Izumikawa, and H. Kakeya et al. Azithromycin, clarithromycin and telithromycin inhibit MUC5AC induction by Chlamydophila pneumoniae in airway epithelial cells Pulm Pharmacol Ther 22 2009 580 586
195. S. Moriya, X.F. Che, S. Komatsu, A. Abe, T. Kawaguchi, and A. Gotoh et al. Macrolide antibiotics block autophagy flux and sensitize to bortezomib via endoplasmic reticulum stress-mediated CHOP induction in myeloma cells Int J Oncol 42 2013 1541 1550
196. E.M. Mtairag, H. Abdelghaffar, C. Douhet, and M.T. Labro Role of extracellular calcium in in vitro uptake and intraphagocytic location of macrolides Antimicrob Agents Chemother 39 1995 1676 1682
197. S. Mulholland, J.B. Gavranich, M.B. Gillies, and A.B. Chang Antibiotics for community-acquired lower respiratory tract infections secondary to Mycoplasma pneumoniae in children Cochrane Database Syst Rev 9 2012 CD004875
198. V. Munic, M. Banjanac, S. Kostrun, K. Nujic, M. Bosnar, and N. Marjanovic et al. Intensity of macrolide anti-inflammatory activity in J774A.1 cells positively correlates with cellular accumulation and phospholipidosis Pharmacol Res 64 2011 298 307
199. V. Munic, Z. Kelneric, L. Mikac, and V. Erakovic Haber Differences in assessment of macrolide interaction with human MDR1 (ABCB1, P-gp) using rhodamine-123 efflux, ATPase activity and cellular accumulation assays Eur J Pharm Sci 41 2010 86 95
200. B.S. Murphy, V. Sundareshan, T.J. Cory, D. Hayes Jr., M.I. Anstead, and D.J. Feola Azithromycin alters macrophage phenotype J Antimicrob Chemother 61 2008 554 560
201. D.M. Murphy, I.A. Forrest, P.A. Corris, G.E. Johnson, T. Small, and D. Jones et al. Azithromycin attenuates effects of lipopolysaccharide on lung allograft bronchial epithelial cells J Heart Lung Transplant 27 2008 1210 1216
202. J.J. Murray, P. Emparanza, E. Lesinskas, M. Tawadrous, and J.D. Breen Efficacy and safety of a novel, single-dose azithromycin microsphere formulation versus 10 days of levofloxacin for the treatment of acute bacterial sinusitis in adults Otolaryngol Head Neck Surg 133 2005 194 200
203. C. Muto, P. Liu, K. Chiba, and T. Suwa Pharmacokinetic-pharmacodynamic analysis of azithromycin extended release in Japanese patients with common respiratory tract infectious disease J Antimicrob Chemother 66 2011 165 174
204. R.V. Naidoo, and P.A. Bryant Not every cough in bronchiolitis season is bronchiolitis BMJ Case Rep 2009 2009
205. R.A. Navarro-Xavier, J. Newson, V.L. Silveira, S.N. Farrow, D.W. Gilroy, and J. Bystrom A new strategy for the identification of novel molecules with targeted proresolution of inflammation properties J Immunol 184 2010 1516 1525
206. Y.C. Nie, H. Wu, P.B. Li, L.M. Xie, Y.L. Luo, and J.G. Shen et al. Naringin attenuates EGF-induced MUC5AC secretion in A549 cells by suppressing the cooperative activities of MAPKs-AP-1 and IKKs-IkappaB-NF-kappaB signaling pathways Eur J Pharmacol 690 2012 207 213
207. C.H. Nightingale Pharmacokinetics and pharmacodynamics of newer macrolides Pediatr Infect Dis J 16 1997 438 443
208. K. Nujic, M. Banjanac, V. Munic, D. Polancec, and V. Erakovic Haber Impairment of lysosomal functions by azithromycin and chloroquine contributes to anti-inflammatory phenotype Cell Immunol 279 2012 78 86
209. K. Nujic, M. Smith, M. Lee, D. Belamaric, L. Tomaskovic, and S. Alihodzic et al. Valosin containing protein (VCP) interacts with macrolide antibiotics without mediating their anti-inflammatory activities Eur J Pharmacol 677 2012 163 172
210. R. Panpanich, P. Lerttrakarnnon, and M. Laopaiboon Azithromycin for acute lower respiratory tract infections Cochrane Database Syst Rev 2008 CD001954
211. M.J. Parnham Antibiotics, inflammation and its resolution: an overview B.K. Rubin, J. Tamaoka, Antibiotics as Anti-Inflammatory and Immunomodulatory Agents 2005 Birkhäuser Verlag Basel 27 47
212. M.J. Parnham, O. Culic, V. Erakovic, V. Munic, S. Popovic-Grle, and K. Barisic et al. Modulation of neutrophil and inflammation markers in chronic obstructive pulmonary disease by short-term azithromycin treatment Eur J Pharmacol 517 2005 132 143
213. A. Pascual, M.C. Conejo, I. Garcia, and E.J. Perea Factors affecting the intracellular accumulation and activity of azithromycin J Antimicrob Chemother 35 1995 85 93
214. T. Peeters, G. Matthijs, I. Depoortere, T. Cachet, J. Hoogmartens, and G. Vantrappen Erythromycin is a motilin receptor agonist Am J Physiol 257 1989 G470 G474
215. T. Pene Dumitrescu, T. Anic-Milic, K. Oreskovic, J. Padovan, K.L. Brouwer, and P. Zuo et al. Development of a population pharmacokinetic model to describe azithromycin whole-blood and plasma concentrations over time in healthy subjects Antimicrob Agents Chemother 57 2013 3194 3201
216. G. Perletti, V. Skerk, V. Magri, A. Markotic, S. Mazzoli, and M.J. Parnham et al. Macrolides for the treatment of chronic bacterial prostatitis: an effective application of their unique pharmacokinetic and pharmacodynamic profile (Review) Mol Med Rep 4 2011 1035 1044
217. H.L. Persson, L.K. Vainikka, M. Sege, U. Wennerstrom, S. Dam-Larsen, and J. Persson Leaky lysosomes in lung transplant macrophages: azithromycin prevents oxidative damage Respir Res 13 2012 83
218. G.L. Piacentini, D.G. Peroni, A. Bodini, R. Pigozzi, S. Costella, and A. Loiacono et al. Azithromycin reduces bronchial hyperresponsiveness and neutrophilic airway inflammation in asthmatic children: a preliminary report Allergy Asthma Proc 28 2007 194 198
219. L.A. Pinto, P.M. Pitrez, F. Luisi, P.P. de Mello, M. Gerhardt, and R. Ferlini et al. Azithromycin therapy in hospitalized infants with acute bronchiolitis is not associated with better clinical outcomes: a randomized, double-blinded, and placebo-controlled clinical trial J Pediatr 161 2012 1104 1108
220. E. Pitsouni, C. Iavazzo, S. Athanasiou, and M.E. Falagas Single-dose azithromycin versus erythromycin or amoxicillin for Chlamydia trachomatis infection during pregnancy: a meta-analysis of randomised controlled trials Int J Antimicrob Agents 30 2007 213 221
221. S. Plesko, M. Banic, V. Plecko, B. Anic, T. Brkic, and H. Renata et al. Effect of azithromycin on acute inflammatory lesions and colonic bacterial load in a murine model of experimental colitis Dig Dis Sci 55 2010 2211 2218
222. D.S. Polancec, V. Munic Kos, M. Banjanac, M. Vrancic, S. Cuzic, and D. Belamaric et al. Azithromycin drives in vitro GM-CSF/IL-4-induced differentiation of human blood monocytes toward dendritic-like cells with regulatory properties J Leukoc Biol 91 2012 229 243
223. J. Pukander, and M. Rautianen Penetration of azithromycin into middle ear effusions in acute and secretory otitis media in children J Antimicrob Chemother 37 Suppl. C 1996 53 61
224. D.A. Raines, A. Yusuf, M.H. Jabak, W.S. Ahmed, Z.A. Karcioglu, and A. El-Yazigi Simultaneous high-performance liquid chromatography analysis of azithromycin and two of its metabolites in human tears and plasma Ther Drug Monit 20 1998 680 684
225. P.S. Ramsey, M.B. Vaules, G.M. Vasdev, W.W. Andrews, and K.D. Ramin Maternal and transplacental pharmacokinetics of azithromycin Am J Obstet Gynecol 188 2003 714 718
226. F. Randow, and C. Munz Autophagy in the regulation of pathogen replication and adaptive immunity Trends Immunol 33 2012 475 487
227. W.A. Ray, K.T. Murray, K. Hall, P.G. Arbogast, and C.M. Stein Azithromycin and the risk of cardiovascular death N Engl J Med 366 2012 1881 1890
228. M. Renna, C. Schaffner, K. Brown, S. Shang, M.H. Tamayo, and K. Hegyi et al. Azithromycin blocks autophagy and may predispose cystic fibrosis patients to mycobacterial infection J Clin Invest 121 2011 3554 3563
229. M.I. Restrepo, E.M. Mortensen, G.W. Waterer, R.G. Wunderink, J.J. Coalson, and A. Anzueto Impact of macrolide therapy on mortality for patients with severe sepsis due to pneumonia Eur Respir J 33 2009 153 159
230. C.M. Ribeiro, H. Hurd, Y. Wu, M.E. Martino, L. Jones, and B. Brighton et al. Azithromycin treatment alters gene expression in inflammatory, lipid metabolism, and cell cycle pathways in well-differentiated human airway epithelia PLoS One 4 2009 e5806
231. K.A. Rodvold, L.H. Danziger, and M.H. Gotfried Steady-state plasma and bronchopulmonary concentrations of intravenous levofloxacin and azithromycin in healthy adults Antimicrob Agents Chemother 47 2003 2450 2457
232. W.O. Rohof, R.J. Bennink, A.A. de Ruigh, D.P. Hirsch, A.H. Zwinderman, and G.E. Boeckxstaens Effect of azithromycin on acid reflux, hiatus hernia and proximal acid pocket in the postprandial period Gut 61 2012 1670 1677
233. L. Saiman, M. Anstead, N. Mayer-Hamblett, L.C. Lands, M. Kloster, and J. Hocevar-Trnka et al. Effect of azithromycin on pulmonary function in patients with cystic fibrosis uninfected with Pseudomonas aeruginosa: a randomized controlled trial JAMA 303 2010 1707 1715
234. L. Saiman, B.C. Marshall, N. Mayer-Hamblett, J.L. Burns, A.L. Quittner, and D.A. Cibene et al. Azithromycin in patients with cystic fibrosis chronically infected with Pseudomonas aeruginosa: a randomized controlled trial JAMA 290 2003 1749 1756
235. V. Saint-Criq, M. Ruffin, C. Rebeyrol, L. Guillot, J. Jacquot, and A. Clement et al. Azithromycin fails to reduce inflammation in cystic fibrosis airway epithelial cells Eur J Pharmacol 674 2012 1 6
236. O. Sakito, J. Kadota, S. Kohno, K. Abe, R. Shirai, and K. Hara Interleukin 1 beta, tumor necrosis factor alpha, and interleukin 8 in bronchoalveolar lavage fluid of patients with diffuse panbronchiolitis: a potential mechanism of macrolide therapy Respiration 63 1996 42 48
237. S. Salman, S.J. Rogerson, K. Kose, S. Griffin, S. Gomorai, and F. Baiwog et al. Pharmacokinetic properties of azithromycin in pregnancy Antimicrob Agents Chemother 54 2010 360 366
238. Y. Sato, K. Kaneko, and M. Inoue Macrolide antibiotics promote the LPS-induced upregulation of prostaglandin E receptor EP2 and thus attenuate macrolide suppression of IL-6 production Prostaglandins Leukot Essent Fatty Acids 76 2007 181 188
239. F. Scaglione, G. Demartini, S. Dugnani, M.M. Arcidiacono, J.P. Pintucci, and F. Fraschini Interpretation of middle ear fluid concentrations of antibiotics: comparison between ceftibuten, cefixime and azithromycin Br J Clin Pharmacol 47 1999 267 271
240. D.J. Serisier, and M.L. Martin Long-term, low-dose erythromycin in bronchiectasis subjects with frequent infective exacerbations Respir Med 105 2011 946 949
241. K. Shakeri-Nejad, and R. Stahlmann Drug interactions during therapy with three major groups of antimicrobial agents Expert Opin Pharmacother 7 2006 639 651
242. R.M. Shepard, and F.C. Falkner Pharmacokinetics of azithromycin in rats and dogs J Antimicrob Chemother 25 Suppl. A 1990 49 60
243. M. Shinkai, M.O. Henke, and B.K. Rubin Macrolide antibiotics as immunomodulatory medications: proposed mechanisms of action Pharmacol Ther 117 2008 393 405
244. M. Shinkai, J. Tamaoki, H. Kobayashi, S. Kanoh, K. Motoyoshi, and T. Kute et al. Clarithromycin delays progression of bronchial epithelial cells from G1 phase to S phase and delays cell growth via extracellular signal-regulated protein kinase suppression Antimicrob Agents Chemother 50 2006 1738 1744
245. A.F. Shorr, M.D. Zilberberg, J. Kan, J. Hoffman, S.T. Micek, and M.H. Kollef Azithromycin and survival in Streptococcus pneumoniae pneumonia: a retrospective study BMJ Open 3 2013
246. E. Singlas Clinical pharmacokinetics of azithromycin Pathol Biol (Paris) 43 1995 505 511
247. K. Skalsky, D. Yahav, A. Lador, N. Eliakim-Raz, L. Leibovici, and M. Paul Macrolides vs. quinolones for community-acquired pneumonia: meta-analysis of randomized controlled trials Clin Microbiol Infect 19 2013 370 378
248. V. Skerk, I. Krhen, M. Lisic, J. Begovac, S. Roglic, and V. Skerk et al. Comparative randomized pilot study of azithromycin and doxycycline efficacy in the treatment of prostate infection caused by Chlamydia trachomatis Int J Antimicrob Agents 24 2004 188 191
249. V. Skerk, I. Marekovic, L. Markovinovic, J. Begovac, V. Skerk, and N. Barsic et al. Comparative randomized pilot study of azithromycin and doxycycline efficacy and tolerability in the treatment of prostate infection caused by Ureaplasma urealyticum Chemotherapy 52 2006 9 11
250. V. Skerk, S. Schonwald, I. Krhen, A. Banaszak, J. Begovac, and J. Strugar et al. Comparative analysis of azithromycin and ciprofloxacin in the treatment of chronic prostatitis caused by Chlamydia trachomatis Int J Antimicrob Agents 21 2003 457 462
251. V. Skerk, S. Schonwald, I. Krhen, L. Markovinovic, B. Barsic, and I. Marekovic et al. Comparative analysis of azithromycin and clarithromycin efficacy and tolerability in the treatment of chronic prostatitis caused by Chlamydia trachomatis J Chemother 14 2002 384 389
252. K.W. Southern, P.M. Barker, A. Solis-Moya, and L. Patel Macrolide antibiotics for cystic fibrosis Cochrane Database Syst Rev 2011 CD002203
253. P. Spagnolo, L.M. Fabbri, and A. Bush Long-term macrolide treatment for chronic respiratory disease Eur Respir J 42 2013 239 251
254. A. Spyridaki, M. Raftogiannis, A. Antonopoulou, T. Tsaganos, C. Routsi, and F. Baziaka et al. Effect of clarithromycin in inflammatory markers of patients with ventilator-associated pneumonia and sepsis caused by Gram-negative bacteria: results from a randomized clinical study Antimicrob Agents Chemother 56 2012 3819 3825
255. P. Srivastava, H. Vardhan, A.R. Bhengraj, R. Jha, L.C. Singh, and S. Salhan et al. Azithromycin treatment modulates the extracellular signal-regulated kinase mediated pathway and inhibits inflammatory cytokines and chemokines in epithelial cells from infertile women with recurrent Chlamydia trachomatis infection DNA Cell Biol 30 2011 545 554
256. R. Stamatiou, K. Boukas, E. Paraskeva, P.A. Molyvdas, and A. Hatziefthimiou Azithromycin reduces the viability of human bronchial smooth muscle cells J Antibiot (Tokyo) 63 2010 71 75
257. R. Stamatiou, E. Paraskeva, K. Boukas, K.I. Gourgoulianis, P.A. Molyvdas, and A.A. Hatziefthimiou Azithromycin has an antiproliferative and autophagic effect on airway smooth muscle cells Eur Respir J 34 2009 721 730
258. W.E. Stamm, C.B. Hicks, D.H. Martin, P. Leone, E.W. Hook III, and R.H. Cooper et al. Azithromycin for empirical treatment of the nongonococcal urethritis syndrome in men. A randomized double-blind study JAMA 274 1995 545 549
259. V. Stepanic, S. Kostrun, I. Malnar, M. Hlevnjak, K. Butkovic, and I. Caleta et al. Modeling cellular pharmacokinetics of 14- and 15-membered macrolides with physicochemical properties J Med Chem 54 2011 719 733
260. D.E. Stover, and D. Mangino Macrolides: a treatment alternative for bronchiolitis obliterans organizing pneumonia? Chest 128 2005 3611 3617
261. M. Sugie, E. Asakura, Y.L. Zhao, S. Torita, M. Nadai, and K. Baba et al. Possible involvement of the drug transporters P glycoprotein and multidrug resistance-associated protein Mrp2 in disposition of azithromycin Antimicrob Agents Chemother 48 2004 809 814
262. K. Sugiyama, R. Shirai, H. Mukae, H. Ishimoto, T. Nagata, and N. Sakamoto et al. Differing effects of clarithromycin and azithromycin on cytokine production by murine dendritic cells Clin Exp Immunol 147 2007 540 546
263. K. Suresh Babu, J. Kastelik, and J.B. Morjaria Role of long term antibiotics in chronic respiratory diseases Respir Med 107 2013 800 815
264. J.A. Sutcliffe, and R. Leclerq Mechanisms of resistance to macrolides, lincosamides, and ketolides W. Schönfeld, H.A. Kirst, Macrolide Antibiotics 2002 Birkhäuser Verlag Basel 281 317
265. H. Svanstrom, B. Pasternak, and A. Hviid Use of azithromycin and death from cardiovascular causes N Engl J Med 368 2013 1704 1712
266. K.F. Tabbara, S.A. al-Kharashi, S.M. al-Mansouri, O.M. al-Omar, H. Cooper, and A.M. el-Asrar et al. Ocular levels of azithromycin 116 1998 1625 1628
267. A. Tait-Kamradt, T. Davies, M. Cronan, M.R. Jacobs, P.C. Appelbaum, and J. Sutcliffe Mutations in 23S rRNA and ribosomal protein L4 account for resistance in pneumococcal strains selected in vitro by macrolide passage Antimicrob Agents Chemother 44 2000 2118 2125
268. J. Tamaoki, J. Kadota, and H. Takizawa Clinical implications of the immunomodulatory effects of macrolides Am J Med 117 Suppl. 9A 2004 5S 11S
269. K. Tateda, R. Comte, J.C. Pechere, T. Kohler, K. Yamaguchi, and C. Van Delden Azithromycin inhibits quorum sensing in Pseudomonas aeruginosa Antimicrob Agents Chemother 45 2001 1930 1933
270. H. Terao, K. Asano, K. Kanai, Y. Kyo, S. Watanabe, and T. Hisamitsu et al. Suppressive activity of macrolide antibiotics on nitric oxide production by lipopolysaccharide stimulation in mice Mediators Inflamm 12 2003 195 202
271. A. Tessmer, T. Welte, P. Martus, M. Schnoor, R. Marre, and N. Suttorp Impact of intravenous {beta}-lactam/macrolide versus {beta}-lactam monotherapy on mortality in hospitalized patients with community-acquired pneumonia J Antimicrob Chemother 63 2009 1025 1033
272. E.M. Thorpe Jr., W.E. Stamm, E.W. Hook III, S.A. Gall, R.B. Jones, and K. Henry et al. Chlamydial cervicitis and urethritis: single dose treatment compared with doxycycline for seven days in community based practises Genitourin Med 72 1996 93 97
273. L. Tomaskovic, M. Komac, O. Makaruha Stegic, V. Munic, J. Ralic, and B. Stanic et al. Macrolactonolides: a novel class of anti-inflammatory compounds Bioorg Med Chem 21 2013 321 332
274. J. Tomazic, V. Kotnik, and B. Wraber In vivo administration of azithromycin affects lymphocyte activity in vitro Antimicrob Agents Chemother 37 1993 1786 1789
275. J. Tong, Z.C. Liu, and D.X. Wang Azithromycin acts as an immunomodulatory agent to suppress the expression of TREM-1 in Bacillus pyocyaneus-induced sepsis Immunol Lett 138 2011 137 143
276. E. Tresse, F.A. Salomons, J. Vesa, L.C. Bott, V. Kimonis, and T.P. Yao et al. VCP/p97 is essential for maturation of ubiquitin-containing autophagosomes and this function is impaired by mutations that cause IBMPFD Autophagy 6 2010 217 227
277. W.C. Tsai, M.B. Hershenson, Y. Zhou, and U. Sajjan Azithromycin increases survival and reduces lung inflammation in cystic fibrosis mice Inflamm Res 58 2009 491 501
278. W.C. Tsai, M.L. Rodriguez, K.S. Young, J.C. Deng, V.J. Thannickal, and K. Tateda et al. Azithromycin blocks neutrophil recruitment in Pseudomonas endobronchial infection Am J Respir Crit Care Med 170 2004 1331 1339
279. W.C. Tsai, and T.J. Standiford Immunomodulatory effects of macrolides in the lung: lessons from in-vitro and in-vivo models Curr Pharm Des 10 2004 3081 3093
280. D. Tyteca, A. Schanck, Y.F. Dufrene, M. Deleu, P.J. Courtoy, and P.M. Tulkens et al. The macrolide antibiotic azithromycin interacts with lipids and affects membrane organization and fluidity: studies on Langmuir-Blodgett monolayers, liposomes and J774 macrophages J Membr Biol 192 2003 203 215
281. D. Tyteca, P. Van Der Smissen, M. Mettlen, F. Van Bambeke, P.M. Tulkens, and M.P. Mingeot-Leclercq et al. Azithromycin, a lysosomotropic antibiotic, has distinct effects on fluid-phase and receptor-mediated endocytosis, but does not impair phagocytosis in J774 macrophages Exp Cell Res 281 2002 86 100
282. D. Tyteca, P. Van Der Smissen, F. Van Bambeke, K. Leys, P.M. Tulkens, and P.J. Courtoy et al. Azithromycin, a lysosomotropic antibiotic, impairs fluid-phase pinocytosis in cultured fibroblasts Eur J Cell Biol 80 2001 466 478
283. P.C. Valery, P.S. Morris, C.A. Byrnes, K. Grimwood, P.J. Torzillo, and P.A. Bauert et al. Long-term azithromycin for Indigenous children with non-cystic-fibrosis bronchiectasis or chronic suppurative lung disease (Bronchiectasis Intervention Study): a multicentre, double-blind, randomised controlled trial Lancet Respir Med 1 2013 610 620
284. F. Van Bambeke, J.P. Montenez, J. Piret, P.M. Tulkens, P.J. Courtoy, and M.P. Mingeot-Leclercq Interaction of the macrolide azithromycin with phospholipids. I. Inhibition of lysosomal phospholipase A1 activity Eur J Pharmacol 314 1996 203 214
285. C. van Delden, T. Kohler, F. Brunner-Ferber, B. Francois, J. Carlet, and J.C. Pechere Azithromycin to prevent Pseudomonas aeruginosa ventilator- associated pneumonia by inhibition of quorum sensing: a randomized controlled trial Intensive Care Med 38 2012 1118 1125
286. A.M. van Eijk, and D.J. Terlouw Azithromycin for treating uncomplicated malaria Cochrane Database Syst Rev 2011 CD006688
287. B.M. Vanaudenaerde, I. Meyts, R. Vos, N. Geudens, W. De Wever, and E.K. Verbeken et al. A dichotomy in bronchiolitis obliterans syndrome after lung transplantation revealed by azithromycin therapy Eur Respir J 32 2008 832 843
288. B.M. Vanaudenaerde, R. Vos, I. Meyts, S.I. De Vleeschauwer, S.E. Verleden, and A. Widyastuti-Willems et al. Macrolide therapy targets a specific phenotype in respiratory medicine: from clinical experience to basic science and back Inflamm Allergy Drug Targets 7 2008 279 287
289. B.M. Vanaudenaerde, W.A. Wuyts, N. Geudens, L.J. Dupont, K. Schoofs, and S. Smeets et al. Macrolides inhibit IL17-induced IL8 and 8-isoprostane release from human airway smooth muscle cells Am J Transplant 7 2007 76 82
290. G.M. Verleden, B.M. Vanaudenaerde, L.J. Dupont, and D.E. Van Raemdonck Azithromycin reduces airway neutrophilia and interleukin-8 in patients with bronchiolitis obliterans syndrome Am J Respir Crit Care Med 174 2006 566 570
291. S.E. Verleden, J. Vandooren, R. Vos, S. Willems, L.J. Dupont, and G.M. Verleden et al. Azithromycin decreases MMP-9 expression in the airways of lung transplant recipients Transpl Immunol 25 2011 159 162
292. S.E. Verleden, R. Vos, V. Mertens, A. Willems-Widyastuti, S.I. De Vleeschauwer, and L.J. Dupont et al. Heterogeneity of chronic lung allograft dysfunction: insights from protein expression in broncho alveolar lavage J Heart Lung Transplant 30 2011 667 673
293. W.J. Videler, L. Badia, R.J. Harvey, S. Gane, C. Georgalas, and F.W. van der Meulen et al. Lack of efficacy of long-term, low-dose azithromycin in chronic rhinosinusitis: a randomized controlled trial Allergy 66 2011 1457 1468
294. N. Villarino, and T. Martin-Jimenez Pharmacokinetics of macrolides in foals J Vet Pharmacol Ther 36 2013 1 13
295. R. Vos, B.M. Vanaudenaerde, A. Ottevaere, S.E. Verleden, S.I. De Vleeschauwer, and A. Willems-Widyastuti et al. Long-term azithromycin therapy for bronchiolitis obliterans syndrome: divide and conquer? J Heart Lung Transplant 29 2010 1358 1368
296. R. Vos, B.M. Vanaudenaerde, S.E. Verleden, S.I. De Vleeschauwer, A. Willems-Widyastuti, and D.E. Van Raemdonck et al. A randomised controlled trial of azithromycin to prevent chronic rejection after lung transplantation Eur Respir J 37 2011 164 172
297. M. Vrancic, M. Banjanac, K. Nujic, M. Bosnar, T. Murati, and V. Munic et al. Azithromycin distinctively modulates classical activation of human monocytes in vitro Br J Pharmacol 165 2012 1348 1360
298. L. Wang, K. Kitaichi, C.S. Hui, K. Takagi, K. Takagi, and M. Sakai et al. Reversal of anticancer drug resistance by macrolide antibiotics in vitro and in vivo Clin Exp Pharmacol Physiol 27 2000 587 593
299. P.L. Wang Roles of oral bacteria in cardiovascular diseases - from molecular mechanisms to clinical cases: treatment of periodontal disease regarded as biofilm infection: systemic administration of azithromycin J Pharmacol Sci 113 2010 126 133
300. A.K. Wierzbowski, D.J. Hoban, T. Hisanaga, M. DeCorby, and G.G. Zhanel The use of macrolides in treatment of upper respiratory tract infections Curr Allergy Asthma Rep 6 2006 171 181
301. A. Wildfeuer, I. Reisert, and H. Laufen Uptake and subcellular distribution of azithromycin in human phagocytic cells. Demonstration of the antibiotic in neutrophil polymorphonuclear leucocytes and monocytes by autoradiography and electron microscopy Arzneimittelforschung 43 1993 484 486
302. A. Willems-Widyastuti, B.M. Vanaudenaerde, R. Vos, E. Dilisen, S.E. Verleden, and S.I. De Vleeschauwer et al. Azithromycin attenuates fibroblast growth factors induced vascular endothelial growth factor via p38(MAPK) signaling in human airway smooth muscle cells Cell Biochem Biophys 67 2013 331 339
303. M. Willenborg, C.K. Schmidt, P. Braun, J. Landgrebe, K. von Figura, and P. Saftig et al. Mannose 6-phosphate receptors, Niemann-Pick C2 protein, and lysosomal cholesterol accumulation J Lipid Res 46 2005 2559 2569
304. E.B. Wilms, D.J. Touw, and H.G. Heijerman Pharmacokinetics of azithromycin in plasma, blood, polymorphonuclear neutrophils and sputum during long-term therapy in patients with cystic fibrosis Ther Drug Monit 28 2006 219 225
305. B.Z. Wilson, A. Anzueto, M.I. Restrepo, M.J. Pugh, and E.M. Mortensen Comparison of two guideline-concordant antimicrobial combinations in elderly patients hospitalized with severe community-acquired pneumonia Crit Care Med 40 2012 2310 2314
306. C. Wong, L. Jayaram, N. Karalus, T. Eaton, C. Tong, and H. Hockey et al. Azithromycin for prevention of exacerbations in non-cystic fibrosis bronchiectasis (EMBRACE): a randomised, double-blind, placebo-controlled trial Lancet 380 2012 660 667
307. W.A. Wuyts, S. Willems, R. Vos, B.M. Vanaudenaerde, S.I. De Vleeschauwer, and M. Rinaldi et al. Azithromycin reduces pulmonary fibrosis in a bleomycin mouse model Exp Lung Res 36 2010 602 614
308. K. Yamada, K. Yanagihara, N. Kaku, Y. Harada, Y. Migiyama, and K. Nagaoka et al. Azithromycin attenuates lung inflammation in a mouse model of ventilator-associated pneumonia by multidrug-resistant Acinetobacter baumannii Antimicrob Agents Chemother 57 2013 3883 3888
309. H. Yamamoto, Y. Naito, M. Okano, T. Kanazawa, H. Takematsu, and Y. Kozutsumi Sphingosylphosphorylcholine and lysosulfatide have inverse regulatory functions in monocytic cell differentiation into macrophages Arch Biochem Biophys 506 2011 83 91
310. K. Yamauchi, Y. Shibata, T. Kimura, S. Abe, S. Inoue, and D. Osaka et al. Azithromycin suppresses interleukin-12p40 expression in lipopolysaccharide and interferon-gamma stimulated macrophages Int J Biol Sci 5 2009 667 678
311. M. Yamaya, A. Azuma, H. Takizawa, J. Kadota, J. Tamaoki, and S. Kudoh Macrolide effects on the prevention of COPD exacerbations Eur Respir J 40 2012 485 494
312. K. Yanagihara, K. Izumikawa, F. Higa, M. Tateyama, I. Tokimatsu, and K. Hiramatsu et al. Efficacy of azithromycin in the treatment of community-acquired pneumonia, including patients with macrolide-resistant Streptococcus pneumoniae infection Intern Med 48 2009 527 535
313. M. Yang, B.R. Dong, J. Lu, X. Lin, and H.M. Wu Macrolides for diffuse panbronchiolitis Cochrane Database Syst Rev 2 2013 CD007716
314. K. Yasuda, L.B. Lan, D. Sanglard, K. Furuya, J.D. Schuetz, and E.G. Schuetz Interaction of cytochrome P450 3A inhibitors with P-glycoprotein J Pharmacol Exp Ther 303 2002 323 332
315. T. Yeung, and S. Grinstein Lipid signaling and the modulation of surface charge during phagocytosis Immunol Rev 219 2007 17 36